The positive AML cell–derived EV biomarkers identified in our experimental data were CD13, CD33, CD34, NPM1, and TGFβ1, as previously reported (18, 20, 53, 54, 55). This evidence concerns the gene TGFB1 and acute myeloid leukemia.